These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2859857)

  • 1. Anti-hyperglycaemic action of BRL 26830, a novel beta-adrenoceptor agonist, in mice and rats.
    Sennitt MV; Arch JR; Levy AL; Simson DL; Smith SA; Cawthorne MA
    Biochem Pharmacol; 1985 Apr; 34(8):1279-85. PubMed ID: 2859857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
    Cawthorne MA; Carroll MJ; Levy AL; Lister CA; Sennitt MV; Smith SA; Young P
    Int J Obes; 1984; 8 Suppl 1():93-102. PubMed ID: 6152558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830.
    Carroll MJ; Lister CA; Sennitt MV; Stewart-Long N; Cawthorne MA
    Diabetes; 1985 Nov; 34(11):1198-204. PubMed ID: 2864298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin.
    Yoshida T
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):237S-241S. PubMed ID: 1345886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of BRL 26830, a novel beta-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in Zucker (fa/fa) rats.
    Smith SA; Levy AL; Sennitt MV; Simson DL; Cawthorne MA
    Biochem Pharmacol; 1985 Jul; 34(14):2425-9. PubMed ID: 2861816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a beta 3-adrenoceptor agonist, BRL 26830A, on insulin and glucagon release in mice.
    Yoshida T; Hiraoka N; Kondo M
    Endocrinol Jpn; 1991 Dec; 38(6):641-6. PubMed ID: 1688048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice.
    Yoshida T; Hiraoka N; Yoshioka K; Hasegawa G; Kondo M
    Endocrinol Jpn; 1991 Aug; 38(4):397-403. PubMed ID: 1687027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased insulin binding and glucose transport in white adipocytes isolated from C57B1/6 ob/ob mice treated with the thermogenic beta-adrenoceptor agonist BRL 26830.
    Young P; King L; Cawthorne MA
    Biochem Biophys Res Commun; 1985 Dec; 133(2):457-61. PubMed ID: 2867764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the beta 3-adrenoceptor agonist BRL 37344 on lipomobilization and plasma glucose levels in conscious fasted rabbits.
    Reverte M; Rivas-Cabañero L
    Can J Physiol Pharmacol; 1996 Mar; 74(3):251-6. PubMed ID: 8773403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
    Young PW; Cawthorne MA; Coyle PJ; Holder JC; Holman GD; Kozka IJ; Kirkham DM; Lister CA; Smith SA
    Diabetes; 1995 Sep; 44(9):1087-92. PubMed ID: 7657033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
    Chang AY; Wyse BM; Gilchrist BJ; Peterson T; Diani AR
    Diabetes; 1983 Sep; 32(9):830-8. PubMed ID: 6354790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the beta-adrenoceptor agonist BRL 26830 on fatty acid synthesis and on the activities of pyruvate dehydrogenase and acetyl-CoA carboxylase in adipose tissues of the rat.
    Wilson S
    Biosci Rep; 1989 Feb; 9(1):111-7. PubMed ID: 2566340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological studies on the hypoglycemic effect of 7,8-dihydro-2-(4-methylpiperazinyl)-4-(1-pyrrolidinyl)-6H-thi opyrano [3,2-d] pyrimidine dimaleate (MTP-1307), a novel hypoglycemic agent.
    Kunoh Y; Ogawa H; Nagasaka M; Asai H; Iguchi A; Niki A; Sakamoto N
    Arch Int Pharmacodyn Ther; 1989; 298():276-87. PubMed ID: 2667487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist.
    Cawthorne MA; Sennitt MV; Arch JR; Smith SA
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):252S-257S. PubMed ID: 1345889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
    Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats.
    Arch JR; Ainsworth AT
    Am J Clin Nutr; 1983 Oct; 38(4):549-58. PubMed ID: 6137948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.
    Liu YL; Cawthorne MA; Stock MJ
    Br J Pharmacol; 1996 Mar; 117(6):1355-61. PubMed ID: 8882636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of three weeks administration of the beta-adrenoceptor agonist BRL 26830A.
    Connacher AA; Bennet WM; Jung RT; Rennie MJ
    Int J Obes Relat Metab Disord; 1992 Sep; 16(9):685-94. PubMed ID: 1356939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro.
    Wu GZ; Hong G; Zhang WP; Zhang HB
    Arzneimittelforschung; 2009; 59(11):550-6. PubMed ID: 20066963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.